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Acute otitis media (AOM) is a source of considerable expense of money and care. Two protocols for the empirical 
treatment of AOM are compared by a cost-effectiveness analysis. In protocol 1, treatment is initiated by a standard- 
spectrum antibiotic (amoxicillin) for 5-7 days; in case of clinical failure, a second treatment is prescribed with a wide- 
spectrum antibiotic (cefaclor) for 7-10 days. In protocol 2, treatment with a standard-spectrum antibiotic is prescribed 
only in case of clinical failure after a 'masterful inactivity' for 3-5 days, then checked on days 5-7, for a prescription of 
a wide-spectrum antibiotic in case of failure. The two protocols have a similar effectiveness, but the cost of protocol 2 
is significantly higher because of a greater expense for medical visits. A low compliance rate is a definite factor of high 
cost-effectiveness ratio. 
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INTRODUCTION 
There are three important reasons to analyze the cost- 
effectiveness of diverse options to manage acute otitis 
media (AOM) therapy in current medical practice. 
First, this condition is very common. The reported 
annual incidence rate of AOM during the first 2 years 
of life is 1.14 episode per year [l]. Approximately 75% 
of the infants had at least one AOM episode, 50% had 
two and 25% had at least three episodes up to the age 
of 2 years [2,3]. Patients with AOM account for 12.4% 
of visits to office-based pediatricians and 1.7% to 
general practitioners. In addition, in about 20% of 
cases, a middle ear effusion persists for 6 weeks after 
treating acute otitis media, resulting in multiple visits 
and prolonged prescriptions [1,4]. 
Second, despite numerous investigations, precise 
diagnostic criteria for AOM remain uncertain [4]. 
With patients aged 0-12 months, the doctor depends 
primarily on examination of tympanic membranes or a 
history of otitis to make a diagnosis. Patients in this age 
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group are the most difficult to examine because of the 
small diameter of their ear canals and the lack of 
cooperation. The child is usually crying and irritable, 
malung otoscopic examination difficult. As the clinician 
struggles to reach a decision as to whether AOM is 
present, the crying by the child will almost certainly 
make the tympanic membrane appear somewhat red. 
The temptation is great to conclude that the child does 
indeed have an ear infection requiring antimicrobial 
treatment. There is often an unspoken agreement 
between the parent and the physician that a pre- 
scription for antibiotics justifies the office visit. Because 
amoxicillin as first-line therapy is considered to be 
extremely safe and benign, even when the diagnosis is 
questionable or uncertain, the pact can be fulfilled with 
minimal risk with satisfaction to both the parent and 
physician. The fact that doctors have been very certain 
of the diagnosis in only 58% of children aged 0-12 
months is disconcerting because this age group has the 
highest incidence of otitis media [4]. Diagnosis 
reliability, however, is important because treatment is 
given even when imprecise criteria are used, when the 
risks of the condition, and the expected benefits of 
treatment, are not established [5]. 
Third, multiple treatment options for AOM have 
been proposed. Early investigators reported better 
outcomes and lesser rates of complications when AOM 
was treated with antibiotics than with a placebo, but 
recent studies haved failed to show significant clinical 
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differences [6,7]. A famous Dutch study [5] which 
reported no difference in outcome among patients 
treated with antibiotics, myringotomy, antibiotics 
combined with myringotomy or placebo may have 
been partly responsible for the low or delayed use of 
antibiotics by Dutch practitioners. The proportion of 
patients prescribed antibiotics varies greatly among the 
countries, from 31.2% in The Netherlands to 98.2% in 
both Australia and New Zealand, as did the duration of 
treatment [4]. The optimal duration of administration 
of antibiotics is uncertain, with 2-3- and 5-day courses 
reported as being as effective as 7-10-day courses [8,9]. 
Prepacking of antibiotics into 5-day aliquots may 
account for the British doctors prescribing antibiotics 
for 5 days [lo]. These mscrepancies have considerable 
consequences for medical care: a 5-day course rather 
than a 10-day one would save more than $50 million 
in the USA, based on the most conservative estimate of 
prescribing rates [4]. 
Many experts recommend amoxicillin for the 
initial empirical treatment of all episodes, although 
some of them limit this to situations where p- 
lactamase-producing organisms are unexpected in the 
light of epidemiologic considerations. Others suggest 
initial treatment with a P-lactamase-stable drug because 
of an increased prevalence of amoxicillin-resistant 
organisms. Another approach, popular in The Nether- 
lands, is to restrict antimicrobial therapy to children 
continuing to have symptoms after 24-72 h of ‘master- 
ful inactivity’ because of a high rate of spontaneous 
resolution of acute symptoms [7]. 
A MEDICO-ECONOMIC ANALYSIS 
Treatment protocols 
The objective is to answer the question of how two 
management options for the initial treatment of AOM 
in children differ with respect to their medico- 
economic efficiency in terms of their cost-effectiveness 
ratios: 
Protocol I-Initial prescription of a standard- 
spectrum drug sensitive to 0-lactamase (treatment 
A) for all patients with AOM: oral amoxicillin 
50-75 mg per kg of body weight daily or 250 mg 
thrice daily, for 7 days with an average clinical 
success rate of 0.90. A second visit V2 is 
scheduled on the fifth or seventh days to check 
the state of the disease, cure or presence of middle 
ear effusion (MEE). If MEE is observed, a new 
treatment (treatment B) is prescribed with a 
wide-spectrum antibiotic, usually cefaclor for 
7-10 days. Patients are re-examined on comple- 
tion of treatment B and 30 days later to determine 
whether they have been successfully cured. 
Protocol 2-Initial symptomatic therapy with 
decongestant nose drops and analgesics, with no 
prescription of antibiotics. The second visit V2 is 
scheduled 3-5 days later to check the disease 
state, cure or presence of MEE/complication. If 
systemic or local signs persist-for approximately 
15% of children more than 2 years of age- 
antibiotic treatment with a standard-spectrum 
antibiotic (treatment A) is prescribed for 5-7 
days, then checked on the seventh to tenth days 
in the same way,as in protocol 1. 
Estimation of costs 
Costs may be evaluated from several perspectives-e.g. 
the patient’s family, the institution, the insurance system 
or society [l]. Despite the fact that the optimal 
perspective is the societal one which encompasses the 
true opportunity costs of all resources used, the present 
analysis will consider direct charges, payments or 
expenditure paid to providers, including physicians, 
pharmacies and hospitals: for physician visits and care, 
tympanocentesis and myringotomy, audiology tests, 
surgery for ventilating tubes (grommets), micro- 
biological procedures and antibiotics. Costs will not 
take into account indirect costs, parental lost wages and 
travel expenses, or the cost of the time that parents 
spend obtaining care for their child. If the initial 
approach fails to cure otitis media, the risk of pro- 
longed MEE and/or complications will be increased, 
and the family will be burdened with medical costs for 
a second medication, additional ofice visit fees and 
time lost from employment. 
This analysis is limited to the direct charges of the 
acute phase of the disease. Antibiotic costs are quanti- 
fied at standard daily acute otitis media dosages, i.e. 
amoxicillin 50 mg/kg and cefaclor 40 mg/kg. Dosage 
is adjusted to a patient weight of 12 kg related to a child 
2 years old. 
The effectiveness of each protocol is the difference 
between its expected result or outcome and the out- 
come of untreated AOM. Cost and outcome are 
estimated in the ‘real world’, e.g. in the actual condi- 
tions of practice with reduced compliance, eventually 
concurrent diseases or treatments and competing risk 
factors. The cost of untreated AOM is assumed to be 
nil. 
Decision tree and cost-effectiveness ratio 
The decision tree is constructed from left to right 
(Figure 1). The square nodes represent ‘choice’ or 
prescription decisions, and the circular nodes represent 
‘chance’ events. The patient is defined as ‘compliant’ 
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Figure 1 Decision tree for comparing the effectiveness of 
two protocols for the treatment of the acute phase of 
AOM. V1 and V2 are the scheduled medical visits and 
periodic otoscopic examinations. Respective probabilities 
are in parentheses ( ). 
when he or she undergoes the regular follow-up visits 
and completes the prescribed treatments. The com- 
pliance rate is the proportion of patients who comply 
with the medical appointments and prescriptions. 
About two thirds of patients (0.67) turn out to be 
compliant with the treatment prescribed and scheduled 
visits [8]. 
Folding back the decision tree from right to left 
gives the average expected cure rate of each protocol: 
protocol 1: 
(1x0.90+ 1 ~0.65X0. 10)~0.67+ 1~0.90X0.33=0.944 
protocol 2 
{ 1x0.85+ [1~0.70+(1~0.60~0.30)]~0.15 j 
x0.67+1XO.85X0.33=0.938 
Cure rates of the two protocols are very close. It 
emerges that the main component of clinical success is 
the compliance rate-e.g. the proportion of patients 
who comply with the follow-up visits and periodic 
otoscopic re-examinations. 
The cure rate according to the compliance rate C 
will be: 
protocol 1 
(1X0.90+ lX0.65XO. lO)XC+ 1X0.90X(l-C) 
=0.90+ 0.065xC 
protocol 2: 
{ 1xO.85+[1x0.70+(1xO.6OxO.3O)]x0.15 jxC 
+lX0.85X(l-C)=0.85+0.132XC 
probabilay of cure 
1.00 7 7 1.00 
0.965 
0.90 3°'g82 0.85 
spontaneous cure rate 
0.85 
compliance rate c 0.75 1.00 0.0 
Figure 2 Expected cure rate of the two protocols 
according to the compliance rate C. 
The probability of cure is a linear function of the 
compliance rate C, illustrated by Figure 2. 
The two protocols give the same expected cure 
rate when the compliance rate C is 0.75, e.g. when 
three out of four patients comply with the medical 
prescriptions and otoscopic periodic examinations. 
When the compliance rate is higher than 0.75, protocol 
2 gives a better cure rate than protocol 1; the reverse is 
true if less than three out of four children comply with 
medical prescriptions. 
Effectiveness is estimated by the difference of the 
clinical success rate of each protocol and the baseline or 
spontaneous cure rate 0.85. 
Protocol 1 effectiveness is: 0.944-0.85=0.094; 
or according to the compliance rate C:  
(0.90+0.065XC)-0.85=(0.05 + 0.065xC) 
Protocol 2 effectiveness is: 0.938-0.85 = 0.088; 
or according to the compliance rate C: 
(0.85 +O . 1 32 XC)-0 .85 = 0.1 32 X C  
The marginal eJectiveness, or difference between the 
effectiveness of protocol 1 and that of protocol 2, is 
(0.05+0.065 xC)-0.132xC=0.05-0.067xC. Outcome 
in favor of protocol 1 is reliable only when the com- 
pliance rate is very low. 
The effectiveness of the two protocols is quite 
similar, at least when the compliance rate value lies 
within a reasonable range. Therefore, the cost-effec- 
tiveness ratios of the two protocols are mostly depend- 
ent on their respective costs, as they may be read on the 
decision tree (Figure 1). 
The cost of protocol 1 firstly includes the cost of 
the visit V1, and the cost of treatment A with 
amoxicillin for 5-7 days. The follow-up expenses, 
cost of V2 and cost of treatment B depend on the 
compliance rate C: 
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The cost of protocol 1 is Vl+A+Cx(V2+0,10xB) 
The cost of protocol 2 includes: 
V1+cx[v2+0.15x(A+V3)+0.30x(B+V4)]. 
The marginal cost is the difference between the costs of 
protocols 1 and 2: 
(Cost of protocol 1)-(cost of protocol 2) 
(V2+0.15x(A+V3)+0.30x(B+V4)] 
=[VI+A+CX(V2+0.10XB)]-[Vl+CX 
=A-CX (0.1 5 XA+O. 2XB+O. 1 5 XV3 +0.3 V4). 
The marginal cost-effectiveness ratio between protocols 
1 and 2 is a hyperbolic function of the compliance rate 
C: 
A-CX(O.15 XA+ 0.2xB+O. 1 5XV3+0.3 XV4) 
0.05-0.067xC. 
Application 
Applied to a child weighing 12 kg, treatment A with 
amoxicillin 50 mg/kg for 5 days uses 3000 mg with a 
cost of 22 ff. Treatment B with cefaclor 20 mg/kg for 
seven days will use two packages with a total cost of 
approximately 80 @ the assumed average cost of a 
medical visit is 150 ff. The cost-effectiveness ratios of 
the two protocols, depending on two compliance rates 
C, should be: 
Compliance Compliance 
rate 0.67 rate 1.00 
protocol 1 278/0.094=2957 ff 330/0.115=2870 ff 
protocol 2 314/0.088=3568 ff 395/0.132=2992 ff 
The cost-effectiveness ratio expresses the cost of 
one clinical cure that is attributable to the medical 
prescription. Medical visits are much more expensive 
than medcal prescriptions. Therefore, in spite of saving 
more medical prescriptions, protocol 2 turns out 
to be more expensive than the systematic antibiotic 
prescription for all AOM episodes according to proto- 
col 1. 
Nonetheless, the real question lies in the respective 
costs of the clinical failure rates of the two protocols, 
or future costs of the treatment protocols of the acute 
phase of AOM. Failure rate=(l-cure rate) is linearly 
related to compliance rate C. The difference between 
the respective failure rates of the protocols 1-2 
The difference between failure rates is negative, in 
favor of protocol 2, as soon as the compliance rate C is 
higher than 0.75. 
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